SCHEMBL2405509

SCHEMBL2405509

Nc1nc(Br)cnc1N1CCN(C(=O)O)CC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NEK2 P51955 2/20 0.39
AKT1 P31749 3/20 0.39
ABL1 P00519 8/20 0.36
BCR P11274 8/20 0.36
PTPN11 Q06124 1/20 0.35
ATR Q13535 1/20 0.35
TP53 P04637 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAP4K4 O95819 1/20 0.33
PI4KB Q9UBF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2317966 0.88 NEK2 (0.43) NEK2AKT1ABL1BCRPTPN11
SCHEMBL2403979 0.85 ABL1 (0.43) AKT1ABL1BCRTP53MEN1
SCHEMBL2404206 0.83 ABL1 (0.35) AKT1ABL1BCRPTPN11ATR
SCHEMBL2320635 0.81 ROCK2 (0.37) ABL1BCRTP53ALDH1A1
SCHEMBL2401956 0.80 KDM4E (0.35) ABL1BCRTP53MEN1ALDH1A1
SCHEMBL2402337 0.80 MAP4K4 (0.52) PTPN11MEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL20446033 0.78 ABL1 (0.46) ABL1BCRALDH1A1PI4KB
SCHEMBL20524606 0.78 OPRK1 (0.41) AKT1ALDH1A1SMN1; SMN2
SCHEMBL2403740 0.77 KDM4E (0.31) AKT1ABL1BCR
SCHEMBL2403738 0.77 KDM4E (0.31) AKT1ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2545058-B1 TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS KALYPSYS INC (US) 2016-08-24 EP disclosed
US-8569300-B2 Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease KALYPSYS INC. (US) 2013-10-29 US disclosed
EP-2545058-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE Kalypsys, Inc. (US) 2013-01-16 EP disclosed
US-20110237565-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-29 US disclosed
WO-2011112766-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237565-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 NEK2 2554/4885AKT1 3738/4885ABL1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.